Healthcare Equipment and Supplies
Company Overview of nContact, Inc.
nContact, Inc., a cardiac ablation device company, develops and manufactures medical devices for the minimally invasive treatment of heart arrhythmias in the United States. It develops Numeris coagulation system with VisiTrax, which is indicated for the coagulation of cardiac tissue; and Numeris guided coagulation system, which is used in closed chest procedures, as well as allows the coil end to be maneuvered along a guidewire, through the paracardioscopic cannula, to endoscopically create bi-atrial lesions. The company was formerly known as nContact Surgical, Inc. and changed its name to nContact, Inc. on January 10, 2011. The company was founded in 2005 and is headquartered in Morrisville...
1001 Aviation Parkway
Morrisville, NC 27560
Founded in 2005
Key Executives for nContact, Inc.
Chief Executive Officer and President
Co-Founder and Vice President of Research & Clinicals
Co-Founder and Vice President of Operations & Development
Vice President of Finance
Director of Regulatory & Quality Assurance
Compensation as of Fiscal Year 2014.
nContact, Inc. Key Developments
nContact, Inc. Announces First Patient Treated in the CONVERGE IDE Clinical Trial
Jan 8 14
nContact, Inc. announced the first patient treated in the CONVERGE IDE Clinical Trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of patients falling into the difficult-to-treat persistent AF population. The CONVERGE Study is designed to investigate the treatment of persistent AF patients with the multidisciplinary Convergent Procedure, an epicardial-endocardial approach that utilizes the collaborative expertise and techniques of an electrophysiologist and cardiothoracic surgeon. The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict outcomes.
nContact, Inc. Presents at Benchmark Company, LLC One-on-One Investor Conference, May-30-2013
May 21 13
nContact, Inc. Presents at Benchmark Company, LLC One-on-One Investor Conference, May-30-2013 . Venue: The Pfister Hotel, 424 E. Wisconsin Avenue, Milwaukee, Wisconsin, United States.
nContact, Inc. Receives Conditional Approval for an Investigational Device Exemption from the U.S. Food and Drug Administration to Begin Enrollment in the Converge Trial, a Multicenter, Prospective, Randomized Study Evaluating Patients with Symptomatic Persistent Atrial Fibrillation
May 9 13
nContact, Inc. announced that it has received conditional approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, a condition that disrupts the ability of the atria (upper chambers of the heart) to beat regularly and pump blood efficiently. AF is estimated to affect 4-6 million people in the U.S., with a majority of these patients falling into the persistent AF population. The CONVERGE study, designed to investigate the epicardial/endocardial Convergent Procedure, combines the cardiac ablation expertise, techniques, and technologies of both electrophysiologists and cardiothoracic surgeons. The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial component of the procedure is completed with no chest incisions, using the proprietary transdiaphragmatic approach that requires a 2-cm incision in the abdomen, providing the surgeon direct visualization to create lesions across the atrium. The CONVERGE trial will randomize patients 2:1 between nContact's epicardial/endocardial Convergent Procedure using the EPi-Sense(R)-AF Guided Coagulation System with VisiTrax(R) and standalone endocardial ablation using fluid-irrigated catheters for the treatment of persistent AF. The primary effectiveness endpoint is freedom from AF, atrial tachycardia, and atrial flutter without the use of new antiarrhythmic drugs. Secondary effectiveness endpoints include the reduction of AF burden and changes in Quality of Life measures from baseline: patients will be followed for 12 months post-procedure. Primary and secondary safety endpoints are the incidence of major adverse events following the initial procedure and through the 12-month follow-up period.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|